CNS Therapeutics

Global Market Trajectory & Analytics

MCP-1835

EXECUTIVE ENGAGEMENTS

POOL

10879
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

1303
Interactions with Platform & by Email

PARTICIPANTS

326
Unique # Participated

VALIDATIONS

82
Responses Validated*

COMPANIES

181
Responses Validated*
* Login for a full stack data experience

DATE

MAY 2021

TABLES

123

PAGES

978

EDITION

18

PRICE

USD 5600

CODE

MCP-1835


COMPETITIVE METRICS

COMPANY

D S N T

% *

Abbott Laboratories, Inc.

AbbVie, Inc.

AC Immune SA

Acadia Pharmaceuticals, Inc.

Acorda Therapeutics, Inc.

Acumen Pharmaceuticals, Inc.

Addex Therapeutics

Aequus Pharmaceuticals, Inc.

Affiris AG

Alexza Pharmaceuticals

View More...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Global CNS Therapeutics Market to Reach $132.1 Billion by 2024

Central Nervous System (CNS) disorder drugs comprise medications employed for treating diseases that impact the spinal cord or the brain. CNS disorders can be classified into pain drugs, neurology, and psychiatry. Neurological drugs treat ailments, such as Alzheimer`s disease, narcolepsy, multiple sclerosis, Parkinson`s disease, migraine, and epilepsy. Psychiatry drugs are generally used for schizophrenia, Attention Deficit Hyperactivity Disorder (ADHD), bipolar disorders, anxiety, and depression. Pain management drugs are employed for treating the pain associated with CNS disorders. Bipolar disorders, depression, anxiety, Alzheimer`s disease, epilepsy, and Parkinson`s disease are the common CNS disorders. Parkinson`s disease is degenerative and is characterized by bradykinesia, akinesia, tremor and rigidity, while epilepsy is a brain condition which results in reoccurring seizures. Such diseases are a result of autoimmune disorders, vascular disorders, trauma, tumors, and neurodegeneration.

Amid the COVID-19 crisis, the global market for CNS Therapeutics is projected to reach US$132.1 Billion by 2024, registering a compounded annual growth rate (CAGR) of 5.1% over the analysis period. The United States represents the largest regional market for CNS Therapeutics, accounting for an estimated 50.2% share of the global total. The market is projected to reach US$70 Billion by the end of the analysis period. China is expected to spearhead growth and emerge as the fastest growing regional market with a CAGR of 7.1% over the analysis period.

The market is on a growth trajectory led by increasing incidence of CNS diseases, rapidly growing aging population, and rising healthcare expenditure. Unmet healthcare needs for detecting and treating CNS conditions brings to fore the untapped potential in the market. Presently, there exists increased demand for new laboratory tests to monitor CNS diseases and also an urgent requirement for developing safe and effective drugs that overthrow limitation of current generation drugs. Companies are therefore investing to develop novel drugs in the neurodegenerative segment. The industry has crossed some milestones in recent years with regard to developing therapies with relatively lesser side effects, convenient drug administration, and efficient performance, although major breakthroughs are still in pipeline. In addition to the reduction in prices in general as a result of patent expiries and the generication of the drugs market, the growing confidence in drug efficacy and clinical evidences is also offering a strong business case for these drugs.

Greater patient compliance as a result of increased awareness about the benefits of the drugs, such as improved quality of life and reduction/prevention of disease co-morbidity, will also help spur patient adherence to prescribed treatment regimes. Acceptance of new therapies and new classes of drugs will additionally benefit the market. In the anti-epilepsy market, for instance, GABA receptor modulators, sodium channel blockers, AMPA receptor antagonist, glutamate blocker, and CRMP-2 modulator, are growing in popularity. Government intervention, especially in developing countries, geared at improving healthcare infrastructure, also infuses confidence in sporting a bullish outlook for the CNS drugs market. Increasing attention towards regenerative therapies for CNS disorders is among the key trends in the market. Such therapies support in healing by replacing or regenerating tissues or human cells, or organs. Several regenerative therapies, such as growth factors, stem cells, and usage of matrix, such as hyaluronic acid, collagen, and fibrin, are emerging.

Therefore, several companies have been focusing on developing regenerative medicines, supported by product innovations and technological advancements. Several existing and new companies are also seen introducing effective medicines for the treatment of specific ailments. Strategic initiatives and partnerships, and launch of novel drugs are the other trends of the market. CNS drugs, specifically for neurodegenerative diseases, are set to become the next big healthcare movement over the coming decades, with Alzheimer`s and Parkinson`s diseases as the two most important therapeutic categories. Though there exists no curative medicine available at present, medications that provide partial relief from symptoms have gained momentum in the recent past. Growing aging population, rising life expectancy, rising incidences of Parkinson`s and Alzheimer`s diseases are the key growth drivers in the markets. Increased demand for combination therapies and growing usage of generics are important trends in the market. Introduction of new class of Alzheimer`s drugs, including anti-amyloid proteins, anti-tau proteins, cholinergic and nicotine receptor agonists, Neuro protective drugs, and GABA receptor modulators, will also help support growth in this space.

The market is also witnessing the launch of novel therapies for the treatment of Parkinson`s disease, such as adenosine and andrenergic agonists, glutamate receptor modulators, and dopamine receptor agonists. Other disease conditions propelling increases in CNS prescriptions, although to a lesser extent, include pain manifestations, psychiatric disorders (schizophrenia, sleep disorders, depression and anxiety), cerebrovascular disorders, stroke, seizures, cognitive and memory disorders, and ailments caused due to injuries and physical trauma.

SELECT PLAYERS

AbbVie Inc.; Alkermes Plc.; Allergan Plc.; AstraZeneca Plc.; Bristol-Myers Squibb; Eisai Co., Ltd.; Eli Lilly and Co.; Endo Pharmaceuticals Inc.; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline Plc; H. Lundbeck A/S; Janssen Pharmaceuticals Inc.; Merck & Co., Inc.; Neurocrine Biosciences, Inc.; Novartis AG; Otsuka Pharmaceutical Co. Ltd.; Pfizer Inc.; Purdue Pharma L.P.; Sanofi; Shire Plc; Sumitomo Dainippon Pharma Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Teva Pharmaceutical Industries Ltd.; UCB Group

SEGMENTS

» Segment (Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer's, Anti-Parkinson's, and Other Segments)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Central Nervous System (CNS) Therapeutics: A Prelude
CNS Therapeutics Exhibit Robust Opportunities amidst Rising Incidence of CNS Disorders
List of FDA Approved CNS Drugs: 2019
List of FDA Approved CNS Drugs: 2018
Patent Expiries of Major Drugs Exert Downward Pressure on the Global CNS Market
Patent Expiries of Leading CNS Drugs: 2008-2022
Developed Markets to Maintain their Dominance
Developing Market to Drive the Market Momentum
MARKET ANALYSIS BY THERAPEUTIC CATEGORY
Anti-Epilepsy Market
Global Market Overview
Regional Landscape
Developed Countries Account for a Major Share of Epilepsy Treatment
Developing Countries Struggle with Low Treatment Rates
New Approvals (2019 and 2018)
Disease Overview
TABLE: Epilepsy Incidence by Type (2019): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy
TABLE: Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy
High Unmet Needs Offer Scope for Market Growth
Treatment
Anti-Epileptic Drugs (AEDs) by Generic Name and Brand Names
Leading Anti-Epileptic Drugs
Leading Anti-Epileptic Drugs and Their Mechanism of Action
Patent Expiries of Major Anti-Epilepsy Drugs
FDA's New Policy for AED Drugs to Bolster Market Growth
AAN Updated Guidelines on New AEDs Use for Treating New Onset Epilepsy (2019)
Select Currently Available Epilepsy Drugs
Select Anti-Epilepsy Drugs (AEDs) in Phase III Trials
Innovative Drugs Needed for Better Treatment Compliance
Abounding Potential for NCEs
A New Research Demonstrates Effectiveness of Gluconate in Treating Neonatal Seizures
FDA Approves Epidiolex (Cannabidiol) - First Drug for Treating Dravet Syndrome and Lennox-Gastaut Syndrome
Refractory Childhood Epilepsy & Pregnancy Epilepsy - Major Concerns
Recent Approvals for Childhood Epilepsy: 2016-2019
Review of Anti-Epilepsy Drugs
CNS Pain Management
Market Overview
Treatment
Drugs Indicated for Pain Management
Select Phase III Ongoing Studies for Cancer Pain
Regional Overview
Players
Combination Therapies Gain Prominence
Key Trends in Chronic Pain Management
Neuropathic Pain Management: Market with High Potential
Select Phase III Ongoing Studies for Neuropathic Pain
Lyrica's Generics Gain FDA Approval
Migraine Market: A Core Vertical in CNS Pain Management
Migraine Care: Select Patent Expiries (2013-2015)
Migraine Completed Phase III Studies: As of October 2019
Migraine Ongoing Phase III Studies: As of October 2019
Select Pain Management Drugs
Flupirtine
Lyrica
Oxycodone
Nucynta ER
Metabotropic Glutamate Receptors (mGluRs)
New Pain Management Drugs
Novartis Presents New Data for Aimovig
Reyvow, Eli Lilly's Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market
Three New Migraine Drugs Obtain FDA Approval
Eli Lilly's Emgality Receives FDA Approval
Anti-Alzheimer's
Market Overview
TABLE: Global Alzheimer's Prevalence by Age Group
Alzheimer's Phase III Completed Studies
Alzheimer's Phase III Ongoing Studies
Treatment for Alzheimer's
Select Leading Drugs for Alzheimer's Disease by Drug Category
Patent Expiries of Leading Alzheimer's Drugs
Aducanumab Marches towards FDA Approval, Following being Abondoned by Biogen a few Months Ago
The Clinical Trials for Aducanumab
Aducanumab: A Promising Drug Which would Revolutionalize the Alzheimer's Market
Alzheimer's Drugs: A Market Plagued with Failures
Promising Compounds with Silver Lining
PRI-002 Gains Success in First Stage of Human Testing for Alzheimer's Disease
Updated FDA Standards Make Way for Increased Alzheimer’s Drug Testing
Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth
Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth
Elenbecestat’s Phase 3 Trials Halted
Novel Drug Delivery Method to the Brain Discovered
Alzheimer's Association Provides Grant to Longeveron
A Review of Select Anti-Alzheimer's Drugs
Aricept
Exelon
Reminyl
Ebixa
Namenda
A Review of the Alzheimer's disease
Alzheimer’s Effect on Brain
Causes for Alzheimer's
Who Are at Risk?
Prevalence of Alzheimer’s Disease
Diagnosis of Alzheimer’s
Anti-Parkinson's
Market Overview
Table: Select Top Selling Drugs for Parkinson's Disease
Nourianz, An Add-on Medication for Treating Episodes of Parkinson’s Disease Secures FDA Approval
Recent Approvals
Novel Drug and a New Delivery Method for Restoring Brain Cells in People Suffering from PD
Xadago - Add-On Therapy for Parkinson’s Disease
NUPLAZID® - The First and the Only Approved Drug for Psychosis related to Parkinson’s disease
Parkinson’s Phase III Completed Studies: As of October 2019
Parkinson's Ongoing Phase III Studies: As of October 2019
Select Anti-Parkinson’s Drugs
Levodopa
Dopamine Agonists
Mirapex
FDA Announces Imminent Discontinuation of Certain Formulations of GSK’s Requip for PD and RSL Treatment
A Review of the Parkinson’s Disease
Prevalence
Symptoms
Causes
Diagnosis
Anti-Depressants
Market Overview
Table: Anti-Depressant Market: Percentage Share Breakdown by Depressive Disorder Type
Anti-Depressant Treatment
Table: Select Top Selling Anti-Depressants in 2018
Select Antidepressants Drugs
Zoloft (Sertraline)
Cymbalta®
Prozac (Fluoxetine)
Effexor (Venlafaxine)
Paxil
Wellbutrin (Bupropion)
Recent Approvals of Anti-Depressants
Esketamine, the Fast Acting Drug for Depression from Janssen Receives FDA Approval
Pipeline Drugs in Phase III for Depressive Disorder: As of October 2019
A Review of Depression
Prevalence of Depression
Causes of Depression
Types of Depressive Disorders
Available Treatment
Anti-Psychotics
Market Overview
Leading Atypical Antipsychotics for the Treatment of Schizophrenia
Pipeline Drugs in Phase III for Schizophrenia: As of October 2019
Pipeline Drugs in Phase III for Bipolar Disorder: As of October 2019
Select Anti-Psychotic Drugs
Zyprexa
Seroquel
Abilify
Clozaril
Risperdal
Risperdal® Consta®
Geodon
Invega Sustenna
Saphris
Latuda
A Review of Anti-Psychotics
Indications of Antipsychotics
An Effective Adjunctive Therapy
Off-label Uses
Efficacy – Marred by Lack of Evidence Base
Types of Antipsychotics
Difference between Typical and Atypical
Atypical Antipsychotics Up Against Typicals
Side Effects of Antipsychotics
Symptoms of Antipsychotics Withdrawal
Bipolar Disorder
Schizophrenia
Other CNS Disorders (Multiple Sclerosis, Attention Deficit Hyperactivity Disorder (ADHD), and Insomnia)
Multiple Sclerosis (MS)
List of Approved Drugs for MS
Patent Expiration Date/Year of the Major MS Drugs
Table: Leading Multiple Sclerosis Drugs (2018): Sales in USD Million
New Approvals
Ocrevus – The First Approved Drug for Primary Progressive Multiple Sclerosis (PPMS)
Multiple Sclerosis: Pipeline Analysis
A Review of Multiple Sclerosis (MS)
Attention Deficit Hyperactivity Disorder (ADHD)
Market Overview
Approved Drugs for ADHD: 2017
Sales of Vyvanse in 2018
Pipeline Drugs in Phase III for ADHD: As of October 2019
Select ADHD Drugs
Vyvanse
Concerta
Adderall
A Review of Attention Deficit Hyperactivity Disorder (ADHD)
Consequences of ADHD
What Leads to ADHD?
Insomnia
Overview
List of Approved Drugs for Insomnia
Pipeline Drugs for Insomnia: As of October 2019
Zolpidem
Eszopiclone
A Review of Insomnia
Prevalence of Insomnia
Therapies for Insomnia
2. FOCUS ON SELECT PLAYERS
AbbVie Inc. (USA)
Alkermes Plc. (Ireland)
Allergan Plc. (Ireland)
AstraZeneca Plc. (UK)
BIAL Group (Portugal)
Bristol-Myers Squibb (USA)
Eisai Co., Ltd. (Japan)
Endo Pharmaceuticals Inc. (USA)
Eli Lilly and Co. (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Fabre-Kramer Pharmaceuticals, Inc. (USA)
GlaxoSmithKline (UK)
H. Lundbeck A/S (Denmark)
Johnson & Johnson (USA)
Janssen Pharmaceuticals, Inc. (USA)
Merck & Co., Inc. (USA)
Neurocrine Biosciences, Inc. (USA)
Novartis AG (Switzerland)
Otsuka Pharmaceutical Co., Ltd. (Japan)
Pfizer, Inc. (USA)
Purdue Pharma L.P. (USA)
Sanofi (France)
Sumitomo Dainippon Pharma Co., Ltd. (Japan)
Sunovion Pharmaceuticals, Inc. (USA)
Takeda Pharmaceutical Co., Ltd. (Japan)
Teva Pharmaceutical Industries Ltd. (Israel)
UCB S.A., (Belgium)
3. MARKET TRENDS & DRIVERS
Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand
TABLE: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
Increased Spending on Prescription Drugs Bodes Well for the CNS Therapeutics Market
Rising Healthcare Expenditure to Boost CNS Therapeutics Market
TABLE: World Healthcare Expenditure (In US$ Trillion) for the Years 2017, 2019, 2021 & 2023
TABLE: Per Capita Healthcare Expenditure (in $) by Select Countries for 2018
Growing Middle Class Population in Emerging Regions to Spur the Market
TABLE: Global Middle Class Population (In Million) by Region for the Years 2020, 2025 and 2030
TABLE: Global Middle Class Spending (US$ Trillion) by Region for the Years 2020, 2025, 2030
Growing Penetration of Generic Drugs Emerges as a Key Trait
TABLE: Global Spending on Generic Drugs Vis-à-vis Branded Drugs (2019): Percentage Share Breakdown of Dollar Spending by Drug Category
Developments in CNS Drug Delivery Technologies Bode Well for the CNS Drugs Market
Understanding of BBB Cell Biology & Its Positive Impact on Epilepsy Drugs: A Case-in-Point
Pharma Companies: Seeking New Tools to Offset Pressure on Drug Pipelines
Awareness Campaigns Launched by Pharma Companies to Benefit the Market…
Music and Memory Programs Positively Impact Alzheimer’s Disease (AD) and Related Dementia (ADRD) Patients
New Method to Isolate Active Compounds Related to Alzheimers from Plant Medicines
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for CNS Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for CNS Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Pain Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Pain Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Pain Management by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Anti-Psychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Anti-Psychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Anti-Psychotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Anti-Depressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Anti-Depressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Anti-Depressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Anti-Epilepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Anti-Epilepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Anti-Epilepsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Anti-Alzheimer`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Anti-Alzheimer`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Anti-Alzheimer`s by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Anti-Parkinson`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Anti-Parkinson`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Anti-Parkinson`s by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
UNITED STATES
Aging Population: A Strong Demographic Driver
TABLE: North American Elderly Population by Age Group (1975-2050)
The Largest CNS Therapeutics Market Globally
Patent Expiries of Leading CNS Drugs in the US
Focus on Select Markets
Alzheimer’s Market
Anti-depressant Drugs
Usage of Antidepressants Surges in the US
Anti-Epilepsy Market
Epilepsy - A Major Concern for the Healthcare Industry
A Glance at Epilepsy Statistics
Anti-Epilepsy Drugs
Epilepsy in Children
Growing Competition from Generics
Pain Management Market
Consumers in the US Seek Different Options for Chronic Pain Management
Neuropathic Pain Market
Anti-Psychotic Drugs Market
Mental Illnesses - Epidemiology
Facts & Figures
Popular Antipsychotic Drugs in the US
Surging Off-label Prescriptions
Generics Occupy Front Seat
Rising Antipsychotic Use among Children - A Cause of Concern
ADHD Market
Select Available ADHD Drugs in the US
TABLE: The US ADHD Drugs Market by Drug Category (2019E): Market Share Breakdown of Total Prescription Sales for Stimulants (Amphetamines and Methylphenidates) and Non-Stimulants
TABLE: The US ADHD Drugs Market by Type (2019E): Market Share Breakdown of Total Prescription Sales for Branded & Generic Drugs Groups
Adult ADHD Drugs Continue to Widen their Share
Market Analytics
USA Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
CANADA
CNS Diseases: Facts & Figures
Canada Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
CHINA
China: The Primary Market for CNS Drugs in Asia-Pacific
Select Anti-Schizophrenia Drugs Available in China
Other Available CNS Drugs in China
China Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
EUROPE
European Patent Expiries of Select CNS Drugs
Pain Management Market
Neuropathic Pain Market Witnesses Foray of Generics
Anti-Psychotics Market
Demand for Antipsychotics for Bipolar Disorder Upbeat
Ageing Population Boosts Demand
TABLE: 65+ Population as Percentage of Total Population for Major Countries in Europe: As on June 2019
Europe Current & Future Analysis for CNS Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe Historic Review for CNS Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
ITALY
Market Snapshots
Italy Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
UNITED KINGDOM
NICE Recommendations on CNS Therapeutics
UK Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
SPAIN
Spain Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Spain Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
RUSSIA
Russia Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Russia Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
ASIA-PACIFIC
India & China Offer Significant Growth Opportunities
Growing Antipsychotics Market in Asia
Asia-Pacific Current & Future Analysis for CNS Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for CNS Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
AUSTRALIA
Australia Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Australia Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
INDIA
India Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
India Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
SOUTH KOREA
South Korea Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
REST OF ASIA-PACIFIC
Rest of Asia-Pacific Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
LATIN AMERICA
Latin America Current & Future Analysis for CNS Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Latin America Historic Review for CNS Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
Latin America Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
ARGENTINA
Argentina Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
BRAZIL
Brazil Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
MEXICO
Mexico Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
REST OF LATIN AMERICA
Rest of Latin America Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
MIDDLE EAST
Middle East Current & Future Analysis for CNS Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Middle East Historic Review for CNS Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
Middle East Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
IRAN
Iran Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Iran Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
ISRAEL
Israel Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Israel Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
SAUDI ARABIA
Saudi Arabia Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
UNITED ARAB EMIRATES
UAE Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UAE Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
REST OF MIDDLE EAST
Rest of Middle East Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
AFRICA
Africa Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Africa Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
Total Companies Profiled: 181 (including Divisions/Subsidiaries - 181)

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com